In the latest trading session, Gilead Sciences (GILD) closed at $109.06, marking a -2.7% move from the previous day. This change lagged the S&P 500's daily loss of 0.4%. Meanwhile, the Dow lost 0.98%, and the Nasdaq, a tech-heavy index, added 0.18%. Coming into today, shares of the HIV and hepatitis C drugmaker had gained 1.14% in the past month. In that same time, the Medical sector lost 1.56%, while the S&P 500 gained 4.97%. Investors should also pay attention to any latest changes in analyst estimates fo ...

股票表现 - 吉利德科学(GILD)过去一个月股价回报率为-6.4%，同期标普500指数下跌0.2%，所属的Zacks医疗-生物医学与遗传学行业下跌6.2% [2] - 公司股票近期受到市场高度关注，成为Zacks平台上搜索量最高的股票之一 [1] 盈利预测 - 当前季度每股收益预期为1.99美元，同比下降1%，过去30天共识预期上调1% [5] - 当前财年每股收益预期7.91美元，同比大幅增长71.2%，过去30天预期上调0.5% [5] - 下一财年每股收益预期8.39美元，同比增长6.1%，过去30天预期上调1% [6] - 分析师盈利预测修正与短期股价走势存在强相关性 [4] 收入预测 - 当前季度收入预期70亿美元，同比增长0.6% [11] - 当前财年收入预期285.1亿美元，同比下降0.8% [11] - 下一财年收入预期297.8亿美元，同比增长4.5% [11] 近期业绩 - 上季度报告收入66.7亿美元，同比下降0.3%，低于共识预期68.4亿美元(-2.46%) [12] - 上季度每股收益1.81美元，去年同期为-1.32美元，略低于共识预期(-0.55%) [12] - 过去四个季度中，三次超过每股收益共识预期，三次超过收入共识预期 [13] 估值分析 - 公司估值指标显示股票相对同行存在折价，Zacks价值风格评分为B级 [17] - 估值方法包括市盈率(P/E)、市销率(P/S)和市现率(P/CF)与历史水平和同业比较 [15]